Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 288

1.

Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.

Torrico M, Aguilar L, Sevillano D, Giménez MJ, Alou L, González N, Cafini F, Cleeland R, Prieto J.

Int J Antimicrob Agents. 2011 Apr;37(4):332-8. doi: 10.1016/j.ijantimicag.2010.12.007.

PMID:
21388792
[PubMed - indexed for MEDLINE]
2.

Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.

Torrico M, Giménez MJ, González N, Alou L, Sevillano D, Cafini F, Prieto J, Cleeland R, Aguilar L.

Int J Antimicrob Agents. 2010 Feb;35(2):131-7. doi: 10.1016/j.ijantimicag.2009.09.021. Epub 2009 Dec 16.

PMID:
20006469
[PubMed - indexed for MEDLINE]
3.

In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.

Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.

J Antimicrob Chemother. 2007 Jun;59(6):1185-9. Epub 2007 Apr 5.

PMID:
17412725
[PubMed - indexed for MEDLINE]
Free Article
4.

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).

Sader HS, Becker HK, Moet GJ, Jones RN.

Diagn Microbiol Infect Dis. 2010 Mar;66(3):329-31. doi: 10.1016/j.diagmicrobio.2009.09.017.

PMID:
20159377
[PubMed - indexed for MEDLINE]
5.
6.

Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).

Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.

Int J Antimicrob Agents. 2007 Aug;30(2):143-9. Epub 2007 May 24.

PMID:
17531446
[PubMed - indexed for MEDLINE]
8.
10.

Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.

Sader HS, Jones RN, Rossi KL, Rybak MJ.

J Antimicrob Chemother. 2009 Nov;64(5):1024-8. doi: 10.1093/jac/dkp319. Epub 2009 Sep 10.

PMID:
19744978
[PubMed - indexed for MEDLINE]
Free Article
11.
12.

Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.

Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.

J Antimicrob Chemother. 2009 Aug;64(2):364-9. doi: 10.1093/jac/dkp176. Epub 2009 May 19.

PMID:
19454524
[PubMed - indexed for MEDLINE]
Free Article
13.

Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.

Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH.

J Antimicrob Chemother. 2006 Dec;58(6):1185-92. Epub 2006 Oct 5.

PMID:
17028094
[PubMed - indexed for MEDLINE]
Free Article
14.

Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2009 Nov;64(5):1044-51. doi: 10.1093/jac/dkp289. Epub 2009 Sep 16.

PMID:
19759041
[PubMed - indexed for MEDLINE]
Free Article
15.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

PMID:
21078943
[PubMed - indexed for MEDLINE]
Free PMC Article
16.
18.

In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ.

Antimicrob Agents Chemother. 2010 Sep;54(9):3799-803. doi: 10.1128/AAC.00452-10. Epub 2010 Jun 28.

PMID:
20585126
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.

Appleman MD, Citron DM.

Diagn Microbiol Infect Dis. 2010 Apr;66(4):441-4. doi: 10.1016/j.diagmicrobio.2009.11.008.

PMID:
20226335
[PubMed - indexed for MEDLINE]
20.

Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.

Rose WE, Rybak MJ, Tsuji BT, Kaatz GW, Sakoulas G.

J Antimicrob Chemother. 2007 Jun;59(6):1190-3. Epub 2007 Apr 13.

PMID:
17434881
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk